Agents with angiogenic and wound healing activity
View Patent ↗The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.
1. A method for treating a wound or promoting angiogenesis in a subject in need thereof, comprising administering an amount of a βB2 crystallin protein or an angiogenic fragment thereof to the subject, effective to treat the wound or promote angiogenesis in the subject, wherein the βB2 crystallin protein or an angiogenic fragment thereof comprises one or more Greek key domains of βB2 crystallin.
2. The method according to claim 1 comprising administering βB2 crystallin protein wherein the protein is a modified form of βB2 crystallin having at least 80% amino acid sequence identity with native βB2 crystallin protein.
3. The method according to claim 1 comprising administering an angiogenic fragment of βB2 crystallin.
4. The method according to claim 3 wherein the angiogenic fragment includes all Greek key domains of βB2 crystallin.
5. The method according to claim 3 wherein the angiogenic fragment is an elastase cleavage product of βB2 crystallin.
6. The method according to claim 3 , wherein the angiogenic fragment comprises the C-terminal extension of native βB2 crystallin protein.
7. The method according to claim 6 , wherein the crystallin protein is ovine or bovine crystallin protein.
8. The method according to claim 1 wherein the βB2 crystallin protein is an eye lens crystallin protein.
9. The method according to claim 1 wherein the crystallin protein is a bovine or ovine crystallin protein.
10. The method according to claim 1 wherein the crystallin protein or angiogenic fragment is in a topically acceptable composition, and the composition is topically administered to a wound.
11. The method according to claim 1 being a method for treating a wound in skin of the subject.
12. The method according to claim 1 being a method for promoting angiogenesis in the subject.
13. The method according to claim 1 , wherein the protein is native βB2 crystallin protein.
14. A method for promoting endothelial cell proliferation and/or migration in a subject in need thereof, comprising administering the subject with an effective amount of a βB2 crystallin protein or an angiogenic fragment thereof, thereby promoting endothelial cell proliferation and/or migration in the subject, wherein the βB2 crystallin protein or an angiogenic fragment thereof comprises one or more Greek key domains of βB2 crystallin.
15. The method according to claim 14 comprising administering an effective amount of native βB2 crystallin to the subject.
16. The method according to claim 14 comprising administering an effective amount of βB2 crystallin protein to the subject, the protein being a modified form of βB2 crystallin having at least 80% amino acid sequence identity with native βB2 crystallin.
17. The method according to claim 14 comprising administering an angiogenic fragment of βB2 crystallin to the subject, the angiogenic fragment comprising the C-terminal extension of native βB2 crystallin.
18. The method according to claim 14 or 17 wherein the crystallin protein is a bovine or ovine crystallin protein.
19. A pharmaceutical composition for treating a wound, or promoting angiogenesis, endothelial cell proliferation and/or migration in a subject, comprising an angiogenic fragment of a βB2 crystallin protein, together with a pharmaceutically acceptable carrier, wherein the angiogenic fragment of the βB2 crystallin protein comprises one or more Greek key domains of βB2 crystallin.
20. The composition according to claim 19 comprising an angiogenic fragment of native βB2 crystallin.
21. The composition according to claim 20 wherein the angiogenic fragment comprises the C-terminal extension of native βB2 crystallin.
22. The composition according to claim 19 or 21 wherein the βB2 crystallin protein is bovine or ovine βB2 crystallin.
23. The composition according to claim 19 , wherein the βB2 crystallin protein is a modified form of βB2 crystallin having at least 80% amino acid sequence identity with native βB2 crystallin.